Inuver (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Beclometasone dipropionate binds to glucocorticoid receptors in airway epithelial and inflammatory cells. This interaction modulates gene expression, suppressing the production of cytokines, chemokines, and other mediators that drive airway inflammation, thereby decreasing swelling, mucus production and hyper‑responsiveness.

Formoterol fumarate is a selective long‑acting β2‑adrenergic agonist. It activates β2 receptors on bronchial smooth muscle, stimulating adenylate cyclase and raising intracellular cyclic AMP levels. The rise in cAMP leads to relaxation of smooth muscle and inhibition of mast cell mediator release, providing sustained bronchodilation for up to 12 hours.

The prescribed dose of Inuver is determined individually by a qualified healthcare professional based on the severity of the patient’s asthma or COPD, age, and response to therapy. The prescriber selects the appropriate number of inhalations per day and may adjust the regimen during follow‑up visits. No generic dosing information is provided here.

Safety data for beclometasone dipropionate and formoterol fumarate in pregnancy or lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss risks and consider alternative treatments when appropriate.

To place an order, submit an enquiry on the Inuver product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Compared with single‑component inhalers, the fixed‑dose combination of beclometasone and formoterol offers both anti‑inflammatory and bronchodilator actions in one device, which can improve adherence and simplify regimens. Alternatives such as separate inhaled corticosteroid and short‑acting β2‑agonist inhalers require multiple steps, while other LABA/ICS combos may differ in potency, dosing frequency or device type.

Inuver inhalers should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect the device from moisture and direct sunlight. Keep the inhaler out of reach of children and avoid exposing it to extreme heat or freezing conditions, which could affect the dose‑metering mechanism.

Inuver is delivered via a metered‑dose inhaler. The patient should exhale fully, place the mouthpiece in the mouth, seal lips around it, and press the canister to release a puff while inhaling slowly and deeply. After inhalation, hold the breath for a few seconds, then exhale. The device should be primed according to the manufacturer’s instructions before first use and periodically as recommended.

Inuver is contraindicated in patients with a known hypersensitivity to beclometasone, formoterol, or any excipients in the inhaler. It should also be avoided in individuals who have experienced a severe paradoxical bronchospasm with β2‑agonists. Caution is advised for patients with uncontrolled cardiovascular disorders, such as arrhythmias or hypertension, and for those receiving non‑selective beta‑blockers.